Johnson & Johnson JNJ

$271.22 +0.54 (0.20%)

Valuation

Market cap
652,311,168,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.79
Forward PE
23.19
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
4,086,000
Avg volume
6,819,122
Day's range
$269.26 – $272.25
Shares out
2,409,898,000
Stochastic %K
72%
Beta
0.24
Analysts
Strong Sell
Price target
$281.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Gfywoody Sep 26, 3:50 PM 0 replies
Gebinator Sep 26, 3:00 PM
Who sometimes reminisces the time we spent as kids getting up early to watch Saturday morning cartoons? It seems that ages and ions later some of us are re-living that Saturday morning feeling on ST! Anyhow, with various speculation about potential $SLS m&a activity, particularly with the established 'Top 3' - $JNJ, $MRK, $ABBV -- and with Simpson Healthcare now engaged to coordinate media and likely some of the m&a process, it may be worthwhile reviewing the field of 'dark horse' BP candidates having the ability to potentially out-bid the 'Top 3' - while also having the resources to fully develop GPS/SLS009. Considering the above, which one of the following BPs is the strongest 'dark horse' candidate for the $SLS prize 🏆 ?
1 replies
RyGuy79 Sep 26, 2:41 PM 1 replies
BioTechHealthX Sep 26, 1:06 PM
$JNJ OTTAVA gives Johnson & Johnson a place in soft tissue robotic surgery. FDA authorization opened the door, but hospital budgets, surgeon training and procedure volume will shape its launch. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-just-entered-the-surgical-robot-race-heres-the-catch/
0 replies
Merlintrader Sep 26, 9:09 AM
Ulcerative colitis: who can win room among the immunology giants? $ABBV, $ABVX, $JNJ, $SYRE https://www.merlintrader.com/ulcerative-colitis-abbv-abvx-jnj-syre/
1 replies
SellasgpsCurativeBAT11 Sep 25, 7:21 PM
$RVMD $SLS $JNJ $PFE Big pharmaceutical Suitor BO Monday. Everything in place not to make a move because they don’t want to repeat $RVMD $44 Billion MC post data. ✌️🙏❤️‍🩹
0 replies
focafoca99 Sep 25, 11:25 AM
$JNJ reported five-year treatment-free remission in 50% of early line RRMM patients with CARVYKTI. https://www.rapidticker.com/news/jnj-single-infusion-of-carvykti-ciltacabtagene-83dbd9
0 replies
BioTechHealthX Sep 25, 7:28 AM
$ARAY $SSII $BDX $GMED $JNJ Surgical robots get the headlines, but pharmacy automation and robotic cancer treatment belong in the conversation too. See which 10 stocks made the best medical stocks ranking. https://biotechhealthx.com/biotech-news/top-10-medical-robotics-stocks-to-buy-today/
0 replies